![]() |
![]() |
Macroglobulinemia of WaldenstromDefinition Macroglobulinemia of Waldenstrom is a cancer of the B lymphocytes (a type of white blood cell) that causes overproduction of monoclonal macroglobulin (IgM antibody). Causes, incidence, and risk factors The cause of this disease is unknown. It is characterized by overproduction of IgM, which causes the blood to become too thick (hyperviscosity). This hyperviscosity interferes with blood flow through small blood vessels, which leads to many of the symptoms of the disease. The disease occurs in 5 out of 100,000 people over 50 years old. Symptoms
Additional symptoms that may be associated with this disease: Signs and tests A physical examination may reveal enlarged spleen, liver, and lymph nodes. A retinal eye examination (examination of the eye with an ophthalmoscope) may reveal enlarged (engorged) retinal veins or retinal bleeding (hemorrhages).
Bone lesions are very rare. If they are present, a bone marrow examination will show cells that resemble both lymphocytes and plasma cells. A blood chemistry shows evidence of renal disease (kidney disease). This disease may also alter the results of the following tests:
Treatment Apheresis (in this case, it is called plasmapheresis or plasma exchange) is a procedure for removing unwanted substances from the blood. In macroglobulinemia, it is used to control the symptoms caused by hyperviscosity by removing or reducing the high concentration of IgM. Blood is withdrawn from the person in the same way as for a blood donation, and the blood is passed through a cell separator that removes the plasma (the fluid portion, which contains the antibodies). The formed elements (blood cells) are reconstituted with a plasma substitute or with donated plasma. The reconstituted blood is then returned to the body in a blood transfusion. This is an acute procedure designed to quickly control symptoms. Drug therapy may include Leukeran, Alkeran, Cytoxan, or corticosteroids. Anemia (deficient number of red blood cells), leukopenia (deficient number of white blood cells) and thrombocytopenia (deficient number of platelets) in the later stages of the disease may require the use of packed red cell transfusions, antibiotics, or platelet transfusions. Expectations (prognosis) The median (average) survival is about 5 years. In some people, the disorder may be chronic with few symptoms and slow progression. Complications
Calling your health care provider Call your health care provider if symptoms of this disorder develop. Illustrations
Page Content: Waldenstrom's macroglobulinemia; Macroglobulinemia - primary ; waldenstroms macroglobulinemia |
![]() ![]() ![]() |